{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:39:18Z","timestamp":1793839158626,"version":"4.6.1"},"reference-count":51,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: This review explores the impact of gut microbiota profiles in predicting the response to anti-integrin biologic therapy, particularly vedolizumab, in inflammatory bowel disease (IBD) patients. IBD, encompassing Crohn\u2019s disease and ulcerative colitis, is a chronic inflammatory condition with a growing prevalence linked to industrialization and lifestyle changes. Disruption in the gut microbiota balance, characterized by reduced diversity and altered short-chain fatty acid (SCFA) production, is associated with IBD and its symptoms. Current pharmacological treatments target healing and remission, with vedolizumab offering a gut-selective treatment approach. Methods: A search of the literature was performed on the relationship between anti-integrin treatment and the microbiome profile in IBD. Articles were examined from the PubMed, Medline, Cochrane, and Web of Science databases. Results: This review identified five human studies investigating the relationship between gut microbiome composition, SCFAs, and response to vedolizumab, revealing an increased abundance of beneficial bacteria and levels of SCFAs like butyrate in remission cases. Despite promising findings, the small sample sizes and limited scope of the existing studies highlight the need for larger, comprehensive research. Conclusions: This review underscores the potential of gut microbiome and metabolite profiling as non-invasive biomarkers for IBD severity and treatment outcomes, advocating for personalized therapeutic strategies to enhance efficacy. The insights gained could lead to novel diagnostic and treatment modalities, although further validation is necessary to fully understand the intricate connections between gut microbiota and IBD prognosis.<\/jats:p>","DOI":"10.3390\/pharmaceutics17040476","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:59:00Z","timestamp":1744091940000},"page":"476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Role of Gut Microbiota and Metabolomics in Predicting Response to Vedolizumab in Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.3390","volume":"17","author":[{"given":"Vaidota","family":"Malinauskiene","sequence":"first","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-4760","authenticated-orcid":false,"given":"Elena","family":"Cijauskaite","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Sadauskaite","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-3638","authenticated-orcid":false,"given":"Ieva","family":"Stundiene","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","article-title":"Global burden of inflammatory bowel disease","volume":"5","author":"Jairath","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and Preventing the Global Increase of Inflammatory Bowel Disease","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","article-title":"Environmental triggers in IBD: A review of progress and evidence","volume":"15","author":"Ananthakrishnan","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rooney, C.M., Mankia, K., and Emery, P. (2020). The Role of the Microbiome in Driving RA-Related Autoimmunity. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.538130"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nature09944","article-title":"Enterotypes of the human gut microbiome","volume":"473","author":"Arumugam","year":"2011","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G.A.D., Gasbarrini, A., and Mele, M.C. (2019). What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms, 7.","DOI":"10.3390\/microorganisms7010014"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-042320-021020","article-title":"The Gut Microbiome and Inflammatory Bowel Diseases","volume":"73","author":"Shan","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","article-title":"Fungal microbiota dysbiosis in IBD","volume":"66","author":"Sokol","year":"2017","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Aldars-Garc\u00eda, L., Chaparro, M., and Gisbert, J.P. (2021). Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease. Microorganisms, 9.","DOI":"10.3390\/microorganisms9050977"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s10620-012-2259-4","article-title":"Butyrate Enhances Intestinal Epithelial Barrier Function via Up-Regulation of Tight Junction Protein Claudin-1 Transcription","volume":"57","author":"Wang","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1038\/ncomms7734","article-title":"Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome","volume":"6","author":"Macia","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rivi\u00e8re, A., Selak, M., Lantin, D., Leroy, F., and De Vuyst, L. (2016). Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.00979"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1113\/EP087773","article-title":"Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion","volume":"104","author":"Jaworska","year":"2019","journal-title":"Exp. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Parada Venegas, D., De La Fuente, M.K., Landskron, G., Gonz\u00e1lez, M.J., Quera, R., Dijkstra, G., Harmsen, H.J.M., Faber, K.N., and Hermoso, M.A. (2019). Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01486"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01457-23","DOI":"10.1128\/spectrum.01457-23","article-title":"Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis","volume":"11","author":"Liu","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2019-10","DOI":"10.7573\/dic.2019-10-2","article-title":"Vedolizumab in the treatment of inflammatory bowel disease: Evolving paradigms","volume":"9","author":"Crooks","year":"2020","journal-title":"Drugs Context"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/MIB.0000000000000396","article-title":"Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Cochrane Systematic Review and Meta-analysis","volume":"21","author":"Mosli","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2019.07.025","article-title":"Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases","volume":"157","author":"Aden","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.chom.2021.06.019","article-title":"Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease","volume":"29","author":"Lee","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/apt.17277","article-title":"Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance","volume":"57","author":"Colman","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2023.11.304","article-title":"Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease","volume":"166","author":"Caenepeel","year":"2024","journal-title":"J. Gastro."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MOG.0b013e32832b36eb","article-title":"Pouchitis: Lessons for inflammatory bowel disease","volume":"25","author":"Wu","year":"2009","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Halfvarson, J., Brislawn, C.J., Lamendella, R., V\u00e1zquez-Baeza, Y., Walters, W.A., Bramer, L.M., D\u2019Amato, M., Bonfiglio, F., McDonald, D., and Gonzalez, A. (2017). Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol., 2.","DOI":"10.1038\/nmicrobiol.2017.4"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000441768","article-title":"Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn\u2019s Disease","volume":"93","author":"Takahashi","year":"2016","journal-title":"Digestion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/gutjnl-2016-313235","article-title":"A microbial signature for Crohn\u2019s disease","volume":"66","author":"Pascal","year":"2017","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2287073","DOI":"10.1080\/19490976.2023.2287073","article-title":"Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: A systematic review","volume":"15","author":"Meade","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/ibd\/izaa253","article-title":"Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn\u2019s Disease","volume":"26","author":"Zhuang","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41575-019-0248-1","article-title":"Host\u2013microbiota interactions in inflammatory bowel disease","volume":"17","author":"Neurath","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.chom.2015.09.008","article-title":"Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn\u2019s Disease","volume":"18","author":"Lewis","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/ajg.2014.246","article-title":"Antibiotics Associated With Increased Risk of New-Onset Crohn\u2019s Disease But Not Ulcerative Colitis: A Meta-Analysis","volume":"109","author":"Ungaro","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/19490976.2018.1560753","article-title":"Bacteroides ovatus ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model","volume":"10","author":"Ihekweazu","year":"2019","journal-title":"Gut Microbes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00253-019-09617-1","article-title":"Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in mice","volume":"103","author":"Tan","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1038\/cti.2016.17","article-title":"Regulation of immune cell function by short-chain fatty acids","volume":"5","author":"Fachi","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2011.02.018","article-title":"The Microbiome and Butyrate Regulate Energy Metabolism and Autophagy in the Mammalian Colon","volume":"13","author":"Donohoe","year":"2011","journal-title":"Cell Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1462-2920.13589","article-title":"Formation of propionate and butyrate by the human colonic microbiota","volume":"19","author":"Louis","year":"2017","journal-title":"Environ. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.3748\/wjg.v19.i22.3404","article-title":"Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India","volume":"19","author":"Kumari","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhang, M., Zhou, Q., Dorfman, R.G., Huang, X., Fan, T., Zhang, H., Zhang, J., and Yu, C. (2016). Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0500-x"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.intimp.2017.07.023","article-title":"Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner","volume":"51","author":"Lee","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1053\/j.gastro.2018.12.001","article-title":"Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis","volume":"156","author":"Paramsothy","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cgh.2019.08.063","article-title":"Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review","volume":"18","author":"Estevinho","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_45","first-page":"412","article-title":"Attributes of intestinal microbiota composition and their correlation with clinical primary nonresponse to anti-TNF-\u03b1 agents in inflammatory bowel disease patients","volume":"22","author":"Alatawi","year":"2021","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104158","DOI":"10.1016\/j.isci.2022.104158","article-title":"Bacteroides ovatus colonization influences the abundance of intestinal short chain fatty acids and neurotransmitters","volume":"25","author":"Horvath","year":"2022","journal-title":"iScience"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lazarevi\u0107, S., \u0110anic, M., Al-Salami, H., Mooranian, A., and Mikov, M. (2022). Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.879170"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000505368","article-title":"Nutrition in Inflammatory Bowel Disease","volume":"101","author":"Schreiner","year":"2020","journal-title":"Digestion"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chen, Z., Zheng, X., Wu, X., Wu, J., Li, X., Wei, Q., Zhang, X., Fang, L., Jin, O., and Gu, J. (2021). Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.700570"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/ecco-jcc\/jjw051","article-title":"Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition","volume":"10","author":"Magnusson","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e00188-17","DOI":"10.1128\/msystems.00188-17","article-title":"Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction","volume":"3","author":"Zhou","year":"2018","journal-title":"mSystems"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/4\/476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:06Z","timestamp":1760029866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/4\/476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["pharmaceutics17040476"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17040476","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]}}}